Cytek Biosciences, Inc , a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications.
infoCytek Biosciences is a small cap stock with a total market cap of 1.08B.
infoThey trade on the NASDAQ and had their IPO 2 years and 1 month ago.
infoCytek Biosciences currently employs 699 people.
infoAs of Wednesday, Aug 23 2023, Cytek Biosciences’s share price is $7.93.
News Relating to Cytek Biosciences
Seeking Alpha
Cytek Biosciences, Inc. (CTKB) Q2 2023 Earnings Call Transcript
Saturday Aug 12 2023 at 15:54
Cytek Biosciences, Inc. (NASDAQ:CTKB ) Q2 2023 Results Conference Call August 8, 2023 4:30 PM ET Company Participants Paul Goodson – IR Wenbin Jiang – CEO Patrik Jeanmonod – CFO Conference Call Participants Steven Mah – TD Cowen David Westenberg – Piper Sandler Operator Good day, and thank you for standing by. Welcome to the Cytek Biosciences Second Quarter 2023 Earnings Conference Call.
GlobeNewsWire
Cytek Biosciences to Report Second Quarter 2023 Financial Results on August 8, 2023
Thursday Jul 20 2023 at 17:26
FREMONT, Calif., July 20, 2023 (GLOBE NEWSWIRE) — Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced it will report financial results for the second quarter 2023 after market close on Tuesday, August 8th, 2023. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook.
Seeking Alpha
Cytek Biosciences, Inc. (CTKB) Q1 2023 Earnings Call Transcript
Saturday May 13 2023 at 17:00
Cytek Biosciences, Inc. (NASDAQ:CTKB ) Q1 2023 Earnings Conference Call May 9, 2023 4:30 PM ET Company Participants Paul Goodson – Head Investor Relations Wenbin Jiang – Chief Executive Officer Patrik Jeanmonod – Chief Financial Officer Conference Call Participants David Westenberg – Piper Sandler Stephanie Yan – TD Cowen Operator Good afternoon, and thank you for standing by. Welcome to the Cytek Biosciences First Quarter 2023 Earnings Conference Call.
The Motley Fool
Why Shares of Cytek Biosciences Dropped This Week
Friday May 12 2023 at 15:41
Cytek focuses on cell analysis primarily for research purposes. The company joined the S&P SmallCap 600 Index last month.
Zacks Investment Research
Cytek Biosciences, Inc. (CTKB) Reports Break-Even Earnings for Q1
Tuesday May 09 2023 at 19:07
Cytek Biosciences, Inc. (CTKB) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of $0.03. This compares to earnings of $0.01 per share a year ago.
Zacks Investment Research
Cytek Biosciences, Inc. (CTKB) Soars 13.4%: Is Further Upside Left in the Stock?
Thursday Apr 27 2023 at 04:34
Cytek Biosciences, Inc. (CTKB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn’t suggest further strength down the road.
GlobeNewsWire
Cytek Biosciences to Report First Quarter 2023 Financial Results on May 9, 2023
Thursday Apr 20 2023 at 16:05
FREMONT, Calif., April 20, 2023 (GLOBE NEWSWIRE) — Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the first quarter 2023 after market close on Tuesday, May 9th, 2023. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook.
CNBC Television
Investment in procedural medical devices is safer for valuation, says E Squared’s Les Funtleyder
Thursday Mar 30 2023 at 14:12
Les Funtleyder, portfolio manager for E Squared Capital Management, joins ‘The Exchange’ to discuss big cap pharma’s Q1 performance, the dollar weakness contributing to biotech gains, and investment opportunities in the pharma space.
Zacks Investment Research
Cytek Biosciences, Inc. (CTKB) Q4 Earnings Top Estimates
Tuesday Feb 28 2023 at 21:05
Cytek Biosciences, Inc. (CTKB) delivered earnings and revenue surprises of 40% and 3.07%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewsWire
Cytek Biosciences to Report Fourth Quarter and Full Year 2022 Financial Results on February 28, 2023
Tuesday Feb 07 2023 at 16:05
FREMONT, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) — Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the fourth quarter and full year 2022 after market close on Tuesday, February 28th, 2023. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook.
GlobeNewsWire
Cytek Biosciences to Participate in Upcoming Investor Conferences
Monday Feb 06 2023 at 16:05
FREMONT, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) — Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced the company will be participating in the following investor conferences:
Benzinga
5 Most Cheapest Stocks In The Healthcare Sector: Bio-Techne, Mirati Therapeutics And More – Corcept Therapeutics (NASDAQ:CORT), Cytek Biosciences (NASDAQ:CTKB)
Thursday Dec 15 2022 at 07:19
The most oversold stocks in the healthcare sector presents an opportunity to buy into undervalued companies.
Seeking Alpha
Cytek Biosciences, Inc. (CTKB) Q3 2022 Earnings Call Transcript
Saturday Nov 12 2022 at 16:45
Cytek Biosciences, Inc. (NASDAQ:CTKB ) Q3 2022 Earnings Conference Call November 9, 2022 4:30 PM ET Company Participants Paul Goodson – Head, IR Wenbin Jiang – President, CEO and Chairman Patrik Jeanmonod – CFO Conference Call Participants Tejas Savant – Morgan Stanley Matthew Sykes – Goldman Sachs David Westenberg – Piper Sandler Operator Welcome to Cytek’s Third Quarter 2022 Earnings Call. At this time, all participants are in a listen-only mode.
GlobeNewsWire
Cytek Biosciences to Report Third Quarter 2022 Financial Results on November 9, 2022
Wednesday Oct 26 2022 at 16:05
FREMONT, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) — Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the third quarter 2022 after market close on Wednesday, November 9th, 2022. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook.
GlobeNewsWire
Cytek to Participate in the 20th Annual Morgan Stanley Global Healthcare Conference
Tuesday Aug 30 2022 at 16:05
FREMONT, Calif., Aug. 30, 2022 (GLOBE NEWSWIRE) — Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced the company will be participating in the upcoming 20th Annual Morgan Stanley Global Healthcare Conference in New York, NY.
Seeking Alpha
Cytek Biosciences, Inc. (CTKB) CEO Wenbin Jiang on Q2 2022 Results Earnings Call Transcript
Wednesday Aug 10 2022 at 22:18
Cytek Biosciences, Inc. (NASDAQ:CTKB ) Q2 2022 Earnings Conference Call August 10, 2022 5:00 PM ET Company Participants Paul Goodson – Head, IR Wenbin Jiang – President, CEO and Chairman Patrik Jeanmonod – CFO Conference Call Participants Max Masucci – Cowen & Company Matt Sykes – Goldman Sachs David Westenberg – Piper Sandler Tejas Savant – Morgan Stanley Operator Good day and thank you for standing by. Welcome to the Cytek Biosciences’ Second Quarter 2022 Earnings Conference Call.
Zacks Investment Research
Cytek Biosciences, Inc. (CTKB) Q2 Earnings Surpass Estimates
Wednesday Aug 10 2022 at 18:48
Cytek Biosciences, Inc. (CTKB) delivered earnings and revenue surprises of 50% and 2.85%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Seeking Alpha
Cytek Biosciences Vs. 10x Genomics: 2 Opposing Cell Visualization Investments
Wednesday Jul 27 2022 at 12:23
Cytek and 10x Genomics both offer single cell visualization tools, a growing and important field in modern medicine. However, each company sees huge differences in popularity, financial performance, and valuation, leading to a significant difference in outlook.
GlobeNewsWire
Cytek Biosciences to Report Second Quarter 2022 Financial Results on August 10, 2022
Wednesday Jul 20 2022 at 16:05
FREMONT, Calif., July 20, 2022 (GLOBE NEWSWIRE) — Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the second quarter 2022 after market close on Wednesday, August 10th, 2022. The company’s management will webcast a corresponding conference call beginning at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its results, business developments and outlook.
Seeking Alpha
Cytek Biosciences, Inc. (CTKB) CEO Wenbin Jiang on Q1 2022 Results – Earnings Call Transcript
Wednesday May 11 2022 at 21:13
Cytek Biosciences, Inc. (NASDAQ:CTKB ) Q1 2022 Earnings Conference Call May 11, 2022 5:00 PM ET Company Participants Paul Goodson – Head, IR Wenbin Jiang – President, CEO & Chairman Patrik Jeanmonod – CFO Conference Call Participants Max Masucci – Cowen and Company Matthew Sykes – Goldman Sachs Group David Westenberg – Piper Sandler & Co. Tejas Savant – Morgan Stanley Operator Thank you for standing by, and welcome to the Cytek Biosciences First Quarter 2022 Earnings Conference Call. [Operator Instructions].
GlobeNewsWire
Cytek Biosciences to Report First Quarter Financial Results on May 11, 2022
Thursday Apr 28 2022 at 16:05
FREMONT, Calif., April 28, 2022 (GLOBE NEWSWIRE) — Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the first quarter 2022 after market close on Wednesday, May 11th, 2022. The company’s management will webcast a corresponding conference call beginning at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its results, business developments and outlook.
Seeking Alpha
Cytek Biosciences, Inc.’s (CTKB) CEO Wenbin Jiang on Q4 2021 Results – Earnings Call Transcript
Wednesday Feb 23 2022 at 20:52
Cytek Biosciences, Inc.’s (CTKB) CEO Wenbin Jiang on Q4 2021 Results – Earnings Call Transcript
Benzinga
Boeing And 3 Other Stocks Bought By Insiders
Thursday Feb 17 2022 at 06:42
US stocks closed mixed on Wednesday following the release of minutes from the recent Federal Reserve meeting. Investors, meanwhile, focused on some notable insider trades.
GlobeNewsWire
Cytek Biosciences to Report Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022
Friday Feb 11 2022 at 08:00
FREMONT, Calif., Feb. 11, 2022 (GLOBE NEWSWIRE) — Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the fourth quarter and full year 2021 after market close on Wednesday, February 23rd, 2022. The company’s management will webcast a corresponding conference call beginning at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its results, business developments and outlook.
Zacks Investment Research
Cytek Biosciences, Inc. (CTKB) Forms ‘Hammer Chart Pattern’: Time for Bottom Fishing?
Thursday Nov 25 2021 at 11:30
Cytek Biosciences, Inc. (CTKB) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock’s potential for a turnaround in the near term.
Seeking Alpha
Cytek Biosciences, Inc.’s (CTKB) CEO Wenbin Jiang on Q3 2021 Results – Earnings Call Transcript
Monday Nov 08 2021 at 18:19
Cytek Biosciences, Inc.’s (CTKB) CEO Wenbin Jiang on Q3 2021 Results – Earnings Call Transcript
GlobeNewsWire
Cytek® Biosciences Introduces New 25-Color Immunoprofiling Assay
Thursday Oct 07 2021 at 10:00
Optimized for Cytek Aurora Cell Analysis Systems; Delivers Turnkey Solution for Immunophenotyping Optimized for Cytek Aurora Cell Analysis Systems; Delivers Turnkey Solution for Immunophenotyping
GlobeNewsWire
Cytek Biosciences to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
Thursday Sep 02 2021 at 16:05
FREMONT, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) — Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB) today announced the company will be participating in the Morgan Stanley 19th Annual Global Healthcare Conference.
GlobeNewsWire
Cytek Biosciences Reports Second Quarter 2021 Financial Results
Thursday Sep 02 2021 at 16:03
FREMONT, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) — Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB) today reported financial results for the second quarter ended June 30, 2021.
GlobeNewsWire
Cytek Biosciences Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
Monday Aug 02 2021 at 16:01
FREMONT, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) — Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, announced today that the underwriters of its previously announced initial public offering, which closed on July 27, 2021, have exercised in full their option to purchase 2,184,695 additional shares of common stock at the price to the public of $17.00 per share. With the addition of the full exercise of the underwriters’ option to purchase additional shares, the total number of shares sold in this offering increased to 16,749,330, and the aggregate gross proceeds to Cytek, before deducting underwriting discounts and commissions and estimated offering expenses, were $237 million. The offering consisted of 13,949,401 shares issued and sold by Cytek, and 2,799,929 shares sold by the selling stockholders named in the prospectus. Cytek did not receive any proceeds from the sale of shares by the selling stockholders.
Cytek Biosciences Bankruptcy Risk
The Altman Z-score is a formula that measures a company’s financial health and bankruptcy risk. It assigns a numerical score based on various financial ratios. The Z-score is divided into different zones. If the Z-score is above 2.99, it indicates a lower bankruptcy risk, classifying the company as ‘safe’ or ‘non-distressed’. If the score falls below 1.81, it suggests a higher risk, indicating potential financial distress or bankruptcy. The range between 1.81 and 2.99 is called the ‘gray zone’ or zone of ambiguity.
Learn more at Investopediaopen_in_new
Cytek Biosciences’s Altman Z-score is 7.41 which is in the safe zone. This indicates the company is financially stable and less likely to experience financial distress or bankruptcy.
Derived from SEC.GOV filing dataopen_in_new
Cytek Biosciences Insider Trading
Insider trading is when individuals employed by a company buy or sell its securities following legal procedures and regulations. Company executives, directors, and employees may be permitted to buy or sell shares if they follow specific rules, such as filing a Form 4 with the SEC within two business days.
Learn more at Investopediaopen_in_new
Over the last 3 months, 1 insider has sold $161.40K of common stock in Cytek Biosciences on the stock market with no insider buying.
Derived from SEC.GOV filing dataopen_in_new
Debt & Income Analysis
Income quality measures a company’s operating cash flow to net income ratio. It helps investors and analysts assess the sustainability of a company’s earnings. A high QIR indicates strong cash flows, while a low QIR may indicate non-operating activities driving net income.
Learn more at WallStreetPrepopen_in_new
Cytek Biosciences’s Income Quality of -1.24 is lower than its Industry Group of 0.81 (-253.1% lower)
Cytek Biosciences’s Income Quality of -1.24 is lower than its Major Industry Group of 0.71 (-274.6% lower)
Cytek Biosciences’s Income Quality of -1.24 is lower than its Sector of 0.75 (-265.3% lower)
Derived from SEC.GOV filing dataopen_in_new
Current ratio measures a company’s ability to pay off short-term debt with its current assets (assets that a company expects to use up or convert to cash within a year). It represents the $ amount of current assets a company has for every $1 of short-term debt. A high current ratio above 1.0 indicates that a company can meet its short-term obligations, while a low current ratio below 1.0 suggests difficulty.
Learn more at Investopediaopen_in_new
Cytek Biosciences’s Current Ratio of 7.93 is greater than its Industry Group of 3.01 (163.5% greater)
Cytek Biosciences’s Current Ratio of 7.93 is greater than its Major Industry Group of 3.13 (153.4% greater)
Cytek Biosciences’s Current Ratio of 7.93 is greater than its Sector of 2.6 (205.0% greater)
Derived from SEC.GOV filing dataopen_in_new
Value Analysis
PE ratio (price-to-earnings), measures a company’s stock price relative to its earnings per share. It helps investors evaluate whether its stock is overvalued or undervalued. A higher PE ratio indicates that investors are willing to pay more for a company’s earnings, while a lower PE ratio (above zero) suggests the company could be undervalued.
Learn more at Investopediaopen_in_new
Cannot compare a negative PE Ratio (-180.22 & 10.69)
Cannot compare a negative PE Ratio (-180.22 & -0.58)
Cannot compare a negative PE Ratio (-180.22 & -0.4)
Derived from SEC.GOV filing dataopen_in_new
The PB ratio (price-to-book), measures a company’s stock price relative to its book value (net value of a company’s assets reported on its balance sheet, after subtracting debt) per share. It is used to evaluate a company’s valuation, with a lower PB ratio (above zero) indicating a lower valuation and a higher PB ratio suggesting overvaluation.
Learn more at Investopediaopen_in_new
Cytek Biosciences’s PB Ratio of 2.55 is in line with its Industry Group of 2.33 (9.4% greater)
Cytek Biosciences’s PB Ratio of 2.55 is greater than its Major Industry Group of 1.93 (32.1% greater)
Cytek Biosciences’s PB Ratio of 2.55 is greater than its Sector of 1.62 (57.4% greater)
Derived from SEC.GOV filing dataopen_in_new
Efficiency Analysis
ROE (Return on Equity), is a financial ratio that measures a company’s profitability relative to its shareholders’ equity (the amount of value in a company that belongs to the people who own shares). It indicates how efficiently a company generates profits per unit of equity invested. A high ROE suggests effective use of equity, while a low ROE indicates inefficiency.
Learn more at Investopediaopen_in_new
Cytek Biosciences’s ROE of -0.01 is lower than its Industry Group of 0.02 (-150.0% lower)
Cytek Biosciences’s ROE of -0.01 is greater than its Major Industry Group of -0.09 (88.9% greater)
Cytek Biosciences’s ROE of -0.01 is greater than its Sector of -0.03 (66.7% greater)
Derived from SEC.GOV filing dataopen_in_new
ROCE (Return on Capital Employed), is a financial ratio that measures a company’s profitability relative to the amount of capital invested in its operations. It indicates how well a company is generating profits from its capital investments. A high ROCE suggests effective use of capital, while a low ROCE indicates inefficiency.
Learn more at Investopediaopen_in_new
Cytek Biosciences’s ROCE of -0.03 is lower than its Industry Group of 0.01 (-400.0% lower)
Cytek Biosciences’s ROCE of -0.03 is greater than its Major Industry Group of -0.14 (78.6% greater)
Cytek Biosciences’s ROCE of -0.03 is greater than its Sector of -0.04 (25.0% greater)
Derived from SEC.GOV filing dataopen_in_new